Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMC 002

Next Previous
Drug Profile

IMC 002

Alternative Names: Anti-CD47 mAb - ImmuneOncia Therapeutics; IMC-002

Latest Information Update: 10 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneOncia Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 02 Jun 2025 Efficacy and safety data from a phase Ib trial in Solid tumours released by ImmuneOncia
  • 03 Jun 2024 Efficacy and pharmacodynamics data from a phase I trial in Solid tumors released by ImmuneOncia
  • 09 May 2024 IMC 002 is still in I trials for Lymphoma (Second-line therapy or greeter) and Solid tumours (Metastatic disease, Late-stage disease) in USA and South Korea (NCT04306224)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top